Head of Business Development

Andrew Stelzer

BS Chemistry
University of Toledo
PhD Biophysics and Chemical Biology
University of Michigan

Andrew is a business development expert in the biotechnology and pharmaceutical industries. Most recently, he supported NewCo formation and translational efforts at The Salk Institute for Biological Studies.  Prior to Salk, Andrew developed the partnering strategy for InSphero, a Swiss biotechnology company spun out of ETH Zurich, and co-founded Nymirum, a private venture backed biotechnology company, spun out of the University of Michigan. Andrew holds a Ph.D. in Biophysics and Chemical Biology from the University of Michigan and a B.S. in Chemistry from the University of Toledo.

Resources by this author
No items found.

Join the team transforming healthcare with AI